Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

    ... and del(5q) (P=0.10) cases with controls. Median lenalidomide response duration increased proportionate to C-allele dosage ...

    Research Article last updated 04/08/2015 - 11:21am.

  2. Lenalidomide in MDS: Where Have We Been and Where Are We Going?

    ... with Ari Giagounidis, Questions asked: What is lenalidomide (also known as Revlimid)? Is lenalidomide considered for treating patients with other sub-types of MDS ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  3. Myelodysplastic syndromes: What do hospitalists need to know?

    ... addition of azacitidine , decitabine , and lenalidomide to erythropoiesis-stimulating agents in our armamentarium ...

    Research Article last updated 06/20/2013 - 10:59am.

  4. Myelodysplastic syndromes: a challenging disease for patients and physicians

    ... line treatment of anaemia is erythroid growth factors. Lenalidomide is a highly potent therapy in low-risk MDS with del 5q, ...

    Research Article last updated 07/31/2012 - 1:58pm.

  5. Infections in myelodysplastic syndromes: a review

    ... and the fact that drugs like hypomethylating agents and lenalidomide , which are effective in myelodysplastic syndromes but can ...

    Research Article last updated 07/31/2012 - 1:39pm.

  6. Myelodysplastic syndromes: therapy and outlook

    ... cell transplantation (HSCT), approved therapies such as lenalidomide , azacitidine , and decitabine are available for ...

    Research Article last updated 07/31/2012 - 1:27pm.

  7. Combination strategies in myelodysplastic syndromes.

    ... International Prognostic Scoring System . Currently, lenalidomide , azacitidine , and decitabine are the only ...

    Research Article last updated 04/24/2012 - 2:18pm.

  8. Immunomodulating drugs in myelodysplastic syndromes

    ... drug (IMID) thalidomide and its derivative lenalidomide (LEN) have been used in MDS, principally in lower-risk MDS. ...

    Research Article last updated 01/09/2012 - 2:00pm.

  9. Azacytidine for the treatment of myelodysplastic syndromes in the elderly.

    ... observation alone for patients with low-risk disease, lenalidomide for patients with 5q-syndrome, to 5-azacytidine (5-AZA) for ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.

    ... azacitidine , (2) decitabine , and (3) lenalidomide . Clinical results with each of these agents, plus results ...

    Research Article last updated 10/11/2011 - 5:58pm.